AIM: To investigate the clinicopathological features and prognostic value of lysine specific demethylase 1 (LSD1) in hepatocellular carcinoma (HCC). METHODS: We examined LSD1 expression in 60 paired liver cancer tissues and adjacent noncancerous tissues by quantitative real time polymerase chain reaction (qRT-PCR) and Western blotting. In addition, we analyzed LSD1 expression in 198 HCC samples by immunohistochemistry. The relationship between LSD1 expression, clinicopathological features and patient survival was investigated. RESULTS: Immunohistochemistry, Western blotting, and qRT-PCR consistently confirmed LSD1 overexpression in HCC tissues compared to adjacent non-neoplastic tissues (P < 0.01). Additionally, immunostaining showed more LSD1-positive cells in the higher tumor stage (T3-4) and tumor grade (G3) than in the lower tumor stage (T1-2, P < 0.001) and tumor grade (G1-2, P < 0.001), respectively. Moreover, HCC patients with high LSD1 expression had significantly lower 5-year overall survival rates (P < 0.001) and lower 5-year disease-free survival rates (P < 0.001), respectively. A Cox proportional hazards model further demonstrated that LSD1 over-expression was an independent predictor of poor prognosis for both 5-year disease-free survival [hazards ratio (HR) = 1.426, 95%CI: 0.672-2.146, P < 0.001] and 5-year overall survival (HR = 2.456, 95%CI: 1.234-3.932, P < 0.001) in HCC. CONCLUSION: Our data suggest for the first time that the overexpression of LSD1 protein in HCC tissues indicates tumor progression and predicts poor prognosis.
AIM: To investigate the clinicopathological features and prognostic value of lysine specific demethylase 1 (LSD1) in hepatocellular carcinoma (HCC). METHODS: We examined LSD1 expression in 60 paired liver cancer tissues and adjacent noncancerous tissues by quantitative real time polymerase chain reaction (qRT-PCR) and Western blotting. In addition, we analyzed LSD1 expression in 198 HCC samples by immunohistochemistry. The relationship between LSD1 expression, clinicopathological features and patient survival was investigated. RESULTS: Immunohistochemistry, Western blotting, and qRT-PCR consistently confirmed LSD1 overexpression in HCC tissues compared to adjacent non-neoplastic tissues (P < 0.01). Additionally, immunostaining showed more LSD1-positive cells in the higher tumor stage (T3-4) and tumor grade (G3) than in the lower tumor stage (T1-2, P < 0.001) and tumor grade (G1-2, P < 0.001), respectively. Moreover, HCC patients with high LSD1 expression had significantly lower 5-year overall survival rates (P < 0.001) and lower 5-year disease-free survival rates (P < 0.001), respectively. A Cox proportional hazards model further demonstrated that LSD1 over-expression was an independent predictor of poor prognosis for both 5-year disease-free survival [hazards ratio (HR) = 1.426, 95%CI: 0.672-2.146, P < 0.001] and 5-year overall survival (HR = 2.456, 95%CI: 1.234-3.932, P < 0.001) in HCC. CONCLUSION: Our data suggest for the first time that the overexpression of LSD1 protein in HCC tissues indicates tumor progression and predicts poor prognosis.
Entities:
Keywords:
Hepatocellular carcinoma; Lysine specific demethylase 1; Prognosis; Tumor progression
Authors: Jianxun Wang; Kathleen Scully; Xiaoyan Zhu; Ling Cai; Jie Zhang; Gratien G Prefontaine; Anna Krones; Kenneth A Ohgi; Ping Zhu; Ivan Garcia-Bassets; Forrest Liu; Havilah Taylor; Jean Lozach; Friederike L Jayes; Kenneth S Korach; Christopher K Glass; Xiang-Dong Fu; Michael G Rosenfeld Journal: Nature Date: 2007-03-28 Impact factor: 49.962
Authors: Yujiang Shi; Fei Lan; Caitlin Matson; Peter Mulligan; Johnathan R Whetstine; Philip A Cole; Robert A Casero; Yang Shi Journal: Cell Date: 2004-12-29 Impact factor: 41.582
Authors: Savita Sankar; Emily R Theisen; Jared Bearss; Timothy Mulvihill; Laura M Hoffman; Venkataswamy Sorna; Mary C Beckerle; Sunil Sharma; Stephen L Lessnick Journal: Clin Cancer Res Date: 2014-06-24 Impact factor: 12.531
Authors: Monica Cusan; Sheng F Cai; Helai P Mohammad; Andrei Krivtsov; Alan Chramiec; Evangelia Loizou; Matthew D Witkin; Kimberly N Smitheman; Daniel G Tenen; Min Ye; Britta Will; Ulrich Steidl; Ryan G Kruger; Ross L Levine; Hugh Y Rienhoff; Richard P Koche; Scott A Armstrong Journal: Blood Date: 2018-02-16 Impact factor: 22.113
Authors: Satoi Nagasawa; Anna S Sedukhina; Yuko Nakagawa; Ichiro Maeda; Manabu Kubota; Shigeko Ohnuma; Koichiro Tsugawa; Tomohiko Ohta; Marta Roche-Molina; Juan A Bernal; Ana J Narváez; Anand D Jeyasekharan; Ko Sato Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240